Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna
Two-Day Multiplexing Symposium Brings Together Leading Scientists to Discuss New Developments in Clinical Diagnostics and Life Science Research
OOSTERHOUT, Netherlands, Oct. 13 -- Luminex Corporation (Nasdaq: LMNX), today announced that it will host Planet xMAP Europe 2010, its annual European multiplexing technology symposium, October 20-21, 2010, at The Hofburg in Vienna, Austria. The event will feature scientific sessions, workshops, discussion groups, exhibitions and networking events with scientists and researchers from around the world who are performing groundbreaking work in clinical diagnostics and life science research using Luminex's xMAP® multiplexing technology platform.
"Planet xMAP Europe is an excellent opportunity for scientists to gather and exchange ideas on how xMAP multiplexing technology is revolutionizing their laboratories and research," said Paul C. Ladestein, General Manager European Operations for Luminex. "We look forward to welcoming these leading scientists to our exciting new venue at The Hofburg in Vienna."
Planet xMAP Europe 2010 will feature two days of presentations with six focused session options.
Day One of Planet xMAP Europe 2010, Wednesday, 20 October, will focus on Pathogen Detection, Immunology-Monitoring and HLA-Human Genetics.
The morning session will include the following presentations:
o Professor Sabine Bahn, MD, PhD, MRCPsych, of the Cambridge Centre for Neuropsychiatric Research Institute of Biotechnology, University of Cambridge, UK, "Disease Biomarkers in First-onset Schizophrenia"
o Professor Jean Louis Merlin, PharmD, PhD, of Tumor Biology Unit, Nancy University Centre Alexis Vautrin, Vandoeuvre-les-Nancy, France, "Phosphoprotein array for characterization of Human Tyrosine kinase receptors downstream signaling functionality as response predictive marker to targeted therapy in translational oncology research programs"
o Professor Alex van Belkum, Department of Medical Microbiology and Infectious Diseases Erasmus MC, Rotterdam, The Netherlands, "Multi-parameter assessment of the humoral response to colonisation and infection with opportunistic microbial pathogens from the human Nasopharyngeal cavity"
o Professor Jonas Blomberg, Section of Virology, Department of Medical Sciences, Uppsala University, Sweden, "More for less; multiplex broadly targeted nucleic acid and serology analyses from the same clinical sample"
o Tim Dehne, Vice President of Systems Research and Development, Luminex Corporation, "MAGPIX: The Next Dimension in Multiplexing"
The afternoon session will feature three separate tracks focused on Pathogen Detection, Immunology-Monitoring, and Human Genetics.
Day Two of Planet xMAP Europe 2010, Thursday, 21 October, will focus on Protein and Genomic Research, and xTAG RVP Fast.
The morning session will include the following presentations:
o Carlo M. Croce, MD, Department of Molecular Virology, Immunology and Medical Genetics The Ohio State University Medical Center, Columbus, Ohio, USA, "Causes and consequences of microRNA Dysregulation in cancer"
o Nicholas Haining, Assistant Professor of Pediatrics, Department of Pediatric Oncology Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA, "Gene-expression based high-throughput screening"
o Anna E. Lokshin, PhD, Hillman Cancer Institute, Luminex Core Facility, University of Pittsburgh, USA, "Urine as a source of cancer biomarkers"
The afternoon session will feature a special xTAG RVP Fast Workshop on current and future trends in respiratory viral testing.
For detailed information regarding the Planet xMAP Europe 2010 symposium and agenda, or to register online, please visit www.planetxmap.com.
About Luminex Corporation
Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets. The Company's xMAP technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP can be obtained at www.luminexcorp.com.
Luminex Corporate Contact:
Harriss T. Currie
Vice President, Finance and Chief Financial Officer
512.219.8020
Matthew Scalo
Sr. Director Investor Relations
512.219.8020
mscalo@luminexcorp.com
Luminex Media Contact:
Aaron De Lucia
512-241-2249
aaron.delucia@porternovelli.com
SOURCE Luminex Corp.
Web Site: www.luminexcorp.com
